Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 4-week, open-label, randomized, multi-centre, parallel-group study evaluating the safety and efficacy of 4 actuations symbicort (budesonide/formoterol) HFA pMDI [hydrofluoroalkane pressurised metered-dose inhaler] 40/2.25 microg twice daily, with and without spacer, in children (6-11 years) with asthma.

Next Previous
Trial Profile

A 4-week, open-label, randomized, multi-centre, parallel-group study evaluating the safety and efficacy of 4 actuations symbicort (budesonide/formoterol) HFA pMDI [hydrofluoroalkane pressurised metered-dose inhaler] 40/2.25 microg twice daily, with and without spacer, in children (6-11 years) with asthma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors AstraZeneca

    • Most Recent Events

    • 15 Mar 2012 Actual initiation data changed from Sep 2007 to 15 Aug 2007 as reported by European Clinical Trials Database.
    • 04 Jun 2008 Astrazeneca submitted sNDA to FDA for the long-term maintenace of asthma in children 6-11 years of age.
    • 31 Mar 2008 Status change from in progress to completed, according to clinicaltrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top